Table 1.
Demographic and baseline characteristics of the study patients
| Trebananib dose cohort | ||||
|---|---|---|---|---|
| 3 mg/kg (n = 6) | 10 mg/kg (n = 6) | 30 mg/kg (n = 6) | Total (n = 18) | |
| Sex, n (%) | ||||
| Male | 4 (66.7) | 3 (50.0) | 3 (50.0) | 10 (55.6) |
| Female | 2 (33.3) | 3 (50.0) | 3 (50.0) | 8 (44.4) |
| Age, years | ||||
| Median (range) | 57.5 (40–70) | 52.5 (47–69) | 63.0 (49–66) | 57.5 (40–70) |
| Weight, kg | ||||
| Median (range) | 55.90 (38.1–64.7) | 65.60 (49.6–78.7) | 49.65 (47.0–56.0) | 55.15 (38.1–78.7) |
| Primary tumor type, n (%) | ||||
| Gastric | 3 (50.0) | 0 (0.0) | 3 (50.0) | 6 (33.3) |
| Rectal | 1 (16.7) | 2 (33.3) | 1 (16.7) | 4 (22.2) |
| Pancreatic | 1 (16.7) | 1 (16.7) | 1 (16.7) | 3 (16.7) |
| Colon | 1 (16.7) | 1 (16.7) | 0 (0.0) | 2 (11.1) |
| Bladder | 0 (0.0) | 0 (0.0) | 1 (16.7) | 1 (5.6) |
| Breast | 0 (0.0) | 1 (16.7) | 0 (0.0) | 1 (5.6) |
| Uterine | 0 (0.0) | 1 (16.7) | 0 (0.0) | 1 (5.6) |
| Eastern Cooperative Oncology Group performance status, n (%) | ||||
| 0 | 6 (100.0) | 6 (100.0) | 5 (83.3) | 17 (94.4) |
| 1 | 0 (0.0) | 0 (0.0) | 1 (16.7) | 1 (5.6) |